XML 26 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Total revenue $ 195.1 $ 216.8 $ 381.4 $ 419.1
Costs and expenses:        
Research and development expense 18.8 22.4 40.1 43.5
Change in the fair value of contingent consideration (0.1) 1.0 0.6 1.4
Selling, general, and administrative expense 135.6 135.2 271.1 265.1
Total costs and expenses 203.9 210.7 411.1 411.8
Operating income (loss) (8.8) 6.1 (29.7) 7.3
Other income (expense):        
Interest income 0.8 0.9 1.7 1.6
Interest expense (2.5) (3.4) (5.4) (5.6)
Other (0.9)   (0.3) 1.1
Total other expense: (2.6) (2.5) (4.0) (2.9)
Income (loss) before income tax (11.4) 3.6 (33.7) 4.4
Income tax provision (benefit) (3.1) 1.0 (4.8) 2.6
Net income (loss) (8.3) 2.6 (28.9) 1.8
Net loss attributable to non-controlling interest       (0.1)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (8.3) $ 2.6 $ (28.9) $ 1.9
Earnings (loss) per share:        
Basic $ (0.11) $ 0.04 $ (0.39) $ 0.03
Diluted $ (0.11) $ 0.03 $ (0.39) $ 0.02
Weighted average shares outstanding:        
Basic 74.4 74.2 74.1 73.6
Diluted 74.4 76.5 74.1 76.9
Molecular Diagnostic Testing [Member]        
Total revenue $ 181.1 $ 203.0 $ 353.1 $ 392.0
Costs and expenses:        
Total costs and expenses 41.0 44.0 82.2 86.3
Pharmaceutical and Clinical Services [Member]        
Total revenue 14.0 13.8 28.3 27.1
Costs and expenses:        
Total costs and expenses $ 8.6 $ 8.1 $ 17.1 $ 15.5